Mastabol 200
Mastabol 200 British Dragon — Overview
Mastabol 200 delivers drostanolone enanthate at 200 mg/ml — the long-ester format of the compound better known as Masteron. The active molecule is identical to the propionate version: a 2α-methyl DHT derivative that does not aromatize, does not cause water retention, and works through direct androgen receptor binding to produce hardening, density, and mild dry strength gains in lean conditions. What the enanthate ester changes is the time profile: a plasma half-life of approximately 10–11 days means blood levels are stable on two injections per week, the compound takes two to three weeks to reach steady state, and the cycle window extends comfortably to 10–16 weeks without the injection burden of every-other-day propionate pinning.
This ester format suits a different use case than Mastabol 100. Where the propionate is built for the final 6–10 weeks of a defined peak, the enanthate runs the full length of a sustained lean phase — a 14-week testosterone enanthate cycle, a body recomposition block, a long pre-contest build. It pairs naturally with other long-ester compounds, simplifies injection scheduling, and fits the workflow of users whose priority is sustained steady-state coverage rather than precise short-window timing. Available at Steroid Warehouse alongside Mastabol 100 as part of British Dragon's full drostanolone range.
About the Compound
Drostanolone enanthate carries the same 2α-methyl dihydrotestosterone base as all drostanolone preparations. The enanthate ester — a long-chain fatty acid attached to the 17β-hydroxyl position — dramatically slows hydrolysis from the subcutaneous or intramuscular depot. Where propionate is cleaved within days, enanthate releases drostanolone over a 10–11 day half-life window. The practical consequence is that a Monday/Thursday or Sunday/Wednesday injection schedule maintains plasma drostanolone within a narrow, stable range throughout the week — no pronounced peaks and troughs, no need for daily or every-other-day planning.
Steady state — the point where incoming doses equal clearance and plasma levels stabilize — is reached after approximately three to five half-lives, meaning roughly three to four weeks of consistent dosing. This front-loading period means Mastabol 200's visual and physical effects accumulate gradually over the first month rather than arriving within days as with the propionate format. Users starting a 14-week cycle will notice the compound's contribution building from weeks three to four onward and peaking from weeks eight through twelve when steady state has been sustained longest.
The high concentration — 200 mg/ml compared to Mastabol 100's 100 mg/ml — means injection volumes are smaller for equivalent weekly doses. At 400 mg/week split twice weekly, each injection is 1 ml. This is a practical advantage at higher doses where propionate format injections become voluminous across three to four EOD shots.
What Mastabol 200 Does
The effect profile of drostanolone enanthate is identical to the propionate format — same molecule, same receptor binding, same pharmacodynamics. The difference is the time course over which those effects develop and are sustained:
- Sustained hardening and density over a full lean phase — rather than delivering its cosmetic effect in a compressed pre-contest window, Mastabol 200 builds and maintains the hardening effect across a 10–16 week block. At steady state from weeks four onward, the compound contributes continuously to the dry, dense appearance that drostanolone is known for at low body fat.
- Stable androgenic environment throughout the cycle — the long ester's stable blood levels mean consistent androgen receptor occupancy without the fluctuations of a shorter ester. For lean-phase protocols where maintaining muscle mass in a caloric deficit is the priority, this consistency supports nitrogen retention and prevents the androgenic drops that can accompany propionate trough periods.
- SHBG displacement across the full cycle — the same SHBG-binding affinity that characterizes the propionate version operates throughout a long enanthate cycle, increasing free testosterone bioavailability from a co-administered testosterone base for the full duration of the run.
- Strength maintenance during a cut — in a caloric deficit over a longer period, the androgenic stimulation from sustained drostanolone levels supports strength output and neuromuscular drive, reducing the strength loss typically associated with prolonged cutting phases.
Steady state timeline: expect weeks one through three to function as the build-up phase — blood levels are rising but have not plateaued. The compound's full contribution becomes apparent from week four onward. Cycles shorter than eight weeks do not fully utilize the enanthate ester's pharmacokinetic profile; for those shorter windows, Mastabol 100 BD (propionate) reaches effective levels faster and is the more appropriate choice.
Who It Is For
Mastabol 200 is for users running sustained lean-phase or body recomposition protocols on long-ester testosterone bases who want drostanolone's hardening and anti-SHBG contribution without the injection frequency of the propionate format.
It is most appropriate for:
- Users on long-ester testosterone cycles of 12–16 weeks who want drostanolone alongside throughout, not just in the final phase. Adding Mastabol 200 from week one of a Testabol Enanthate cycle means steady-state drostanolone levels are established by the time the lean phase intensifies in weeks five through eight.
- Body recomposition protocols — longer blocks at maintenance calories where the goal is simultaneous fat reduction and muscle retention over months rather than weeks. The sustained androgenic support from an enanthate-based drostanolone run suits this time horizon better than a short propionate phase.
- Users who prioritize injection convenience — two injections per week versus every-other-day is a meaningful quality-of-life difference across a 12–16 week cycle. With the same compound, same effect, and fewer injection events, Mastabol 200 is the pragmatically easier choice when the competition peak timing is not a constraint.
Choose something else when: the cycle is shorter than 8–10 weeks or timed to a fixed competition date within that window — the enanthate ester's slow onset and long PCT delay make Mastabol 100 BD the better fit. When significant mass and conditioning gains are wanted alongside hardening, Boldabol 200 BD (boldenone undecylenate) covers a longer lean-phase with more meaningful anabolic contribution — at the cost of some aromatization and a different side effect profile requiring AI management.
Mastabol 200 vs Alternatives
| Compound | Key Differences | Choose Mastabol 200 When | Choose Alternative When |
|---|---|---|---|
| Mastabol 200 British Dragon |
Drostanolone enanthate; ~10–11 day half-life; 2× weekly injections; 3–4 wk steady-state build; full lean phase coverage; PCT 14–16 days post last pin | Long lean phase (10–16 wks) on enanthate-based cycle; injection convenience a priority; no fixed near-term competition peak | — |
| Mastabol 100 British Dragon |
Drostanolone propionate; same compound; ~2–3 day half-life; EOD injections; fast onset and clearance; dose adjustable on days notice; PCT in 3–4 days | Short pre-contest window (6–10 wks); fixed competition date; all-propionate stack; drug testing; quick dose response needed | Cycle is 12+ weeks; EOD injections impractical; no fixed peak date → Mastabol 200 |
| Boldabol 200 British Dragon |
Boldenone undecylenate; longer ester (~14 day half-life); aromatizes mildly (requires AI); stronger appetite stimulation; more pronounced anabolic contribution; lean mass + conditioning + vascularity; requires AI management for estrogen | Lean phase with meaningful lean mass addition alongside conditioning; vascularity is a goal; appetite support useful in a long bulk | Pure hardening and density without any mass addition; AI management not wanted; zero aromatization required → Mastabol 200 |
Combinations
| Goal | Stack | Why It Works |
|---|---|---|
| Long lean phase — enanthate stack | Testabol Enanthate (400–500 mg/wk) + Mastabol 200 (400 mg/wk), weeks 1–14; both twice weekly | Both long-ester compounds on a matched injection schedule — Monday and Thursday covers both simultaneously. Drostanolone is present at steady state from week four through the full cycle, contributing hardening and SHBG displacement throughout. Clean stack with no aromatization from either compound; AI need is set by the testosterone dose and the user's aromatization rate, not by drostanolone. |
| Body recomposition block | Testabol Enanthate (300 mg/wk, maintenance) + Mastabol 200 (300–400 mg/wk), 14–16 weeks; caloric maintenance | Modest testosterone dose to maintain hormone function; drostanolone's androgenic support preserves muscle mass and supports fat oxidation in a body recomposition context. The long cycle at maintenance calories requires sustained compound presence — the enanthate ester is appropriate where propionate would require a higher injection burden across the same timeline. |
| EQ + Masteron lean bulk | Testabol Enanthate (500 mg/wk) + Boldabol 200 BD (400 mg/wk) + Mastabol 200 (300 mg/wk), weeks 1–16 | Boldenone brings lean mass accumulation and appetite; Mastabol 200 offsets some of boldenone's aromatization contribution and adds dryness and density across the long cycle. Anastrozole management needed given the two aromatizing compounds in the stack. All three are long-ester, once or twice-weekly compounds — injection scheduling stays manageable throughout. |
Side Effects & Management
The side effect profile of drostanolone enanthate is the same as propionate — same molecule — with one practical difference: because blood levels change slowly, any side effect that emerges also resolves slowly after dose reduction. A propionate user who reduces dose sees blood level changes within days; an enanthate user waits one to two weeks for the same magnitude of change. This makes conservative starting doses and early bloodwork more important than with the short ester.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Androgenic effects (acne, hair) | Drostanolone is a direct-acting DHT derivative — sebaceous stimulation and androgenetic alopecia acceleration are the primary androgenic risks. The enanthate ester means these effects build gradually over the first weeks of the cycle and do not resolve immediately on dose reduction. | Cystic acne: Isotroin (isotretinoin). Hair loss in predisposed users: no pharmacological block available with this compound class — finasteride is ineffective on DHT derivatives. Early signs of androgenic side effects that are unacceptable should prompt dose reduction; expect 1–2 weeks for blood levels to respond. |
| HDL suppression / lipid impact | Non-aromatizing androgens suppress HDL consistently. Across a 14–16 week enanthate cycle, lipid suppression is cumulative. The longer duration compared to a propionate pre-contest run means a mid-cycle lipid check matters more here than in a short 8-week protocol. | Lipid panel at baseline, week 6, and week 12 for cycles of 14+ weeks. Elevated LDL: Atorlip (atorvastatin). Omega-3 supplementation and sustained aerobic training throughout the cycle. Check again 4–6 weeks post-cycle to confirm recovery. |
| Blood pressure | Drostanolone's direct BP impact is modest. In a long-cycle context with a testosterone base and potential erythropoietic activity accumulating over 12–16 weeks, aggregate cardiovascular load warrants regular monitoring. | Monitor BP every two weeks on a long cycle. Sustained readings above 135/85 mmHg: Amlip (amlodipine) 5 mg/day. Hematocrit should be checked mid-cycle on longer runs — if approaching 52%, aerobic training volume and hydration become more critical. |
| Slow side-effect resolution | The enanthate ester's long half-life is an advantage for stability but a disadvantage for rapid course correction. If a side effect appears at week 8, reducing the dose produces a measurable change in blood levels only by weeks 9–10. This is the primary pharmacokinetic trade-off versus the propionate format. | Start at the lower end of the dose range (300 mg/wk) for the first 4 weeks. Confirm tolerability and check bloodwork before increasing to the 400–500 mg/wk target. This front-loaded caution avoids establishing a high steady-state level that then requires a slow, uncomfortable reduction. |
| HPG axis suppression | Fully suppressive throughout the cycle. The longer duration of a typical enanthate cycle means a longer cumulative suppression period than a short propionate run, though PCT recovery from drostanolone-only suppression is generally straightforward. | Structured PCT after a 14–16 day clearance window following the last injection. See section below. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Lipid panel (HDL / LDL) | Baseline; week 6; week 12 (for 14+ week cycles); 4–6 weeks post-cycle | HDL above 35 mg/dL; LDL below 130 mg/dL. The longer cycle duration makes mid-cycle lipid monitoring more important than on a short propionate run. Add Atorlip if LDL exceeds threshold at either mid-cycle check. |
| Hematocrit / CBC | Baseline; week 8; end of cycle | Keep hematocrit below 52%. Long-cycle erythropoietic stimulation from sustained androgen exposure is more relevant here than in a 6–8 week propionate run. A week-8 check catches cumulative elevation before it becomes clinically significant. |
| Blood pressure | Every 2 weeks throughout cycle | Target below 130/80 mmHg. Long-cycle aggregate cardiovascular changes develop gradually — biweekly monitoring catches trends before they require urgent management. |
| LH + FSH | 3–4 weeks post-PCT | Return to normal range confirms HPG axis recovery. After a 14–16 week suppressive cycle, expect recovery to take the full 4-week PCT plus 3–4 additional weeks — total 7–8 weeks from last injection to confirmed recovery in most cases. |
| Total testosterone | 3–4 weeks post-PCT | Return to pre-cycle baseline. Persistent suppression at 10–12 weeks post-last-injection warrants further evaluation regardless of the compounds used. |
PCT — Post-Cycle Therapy
The enanthate ester's 10–11 day half-life means it takes 14–16 days post-last-injection for plasma drostanolone to fall to a level where PCT SERMs can effectively compete. Starting PCT too early — before adequate clearance — reduces its efficacy. When Mastabol 200 is stacked with a long-ester testosterone, PCT timing is set by the testosterone clearance window, which is the same or nearly identical.
| Product | Role in PCT |
|---|---|
| Clomiphene Tablets BD | 50 mg/day weeks 1–2, then 25 mg/day weeks 3–4. Begin 14–16 days after the final injection of Mastabol 200 (or the final injection of the longest-ester compound in the stack). Drives LH and FSH release to restart testicular production. |
| Tamoxifen Tablets BD | 20 mg/day weeks 1–2, then 10 mg/day weeks 3–4. Starts on the same day as Clomiphene. Hypothalamic estrogen receptor blockade restores GnRH pulse frequency. Running both SERMs together produces more reliable axis recovery than either alone across a 4-week PCT window. |
Long-cycle PCT planning: after a 14–16 week cycle, the HPG axis has been suppressed for a meaningfully longer period than after a 6–8 week propionate run. A standard 4-week SERM PCT is appropriate, but LH/FSH and total testosterone should be confirmed by bloodwork 3–4 weeks after PCT completion — not assumed to have recovered based on timing alone.
Practical Summary
- Allow 3–4 weeks for the compound to reach full effect: the enanthate ester means the first month of a Mastabol 200 cycle is a build-up phase. Do not judge the compound's contribution at week two — blood levels are still rising toward steady state. The full effect is experienced from weeks four through the end of the cycle.
- Start at 300 mg/wk and confirm tolerability before escalating: the slow response to dose changes cuts both ways — a high dose that causes unacceptable androgenic sides takes two weeks to meaningfully reduce after a dose cut. Front-load the caution, not the dose.
- Mid-cycle lipid checks are mandatory on long cycles: 12–16 weeks of HDL suppression from a non-aromatizing androgen requires more monitoring than a short propionate run. Weeks 6 and 12 panels catch cumulative lipid changes before they compound further.
- PCT window is 14–16 days, not 3–4: the most common practical mistake with enanthate-ester compounds is starting PCT too early. Calculate 14–16 days from the last Mastabol 200 injection (or the last long-ester compound in the stack) before beginning SERMs.
- Injection volume advantage at higher doses: at 400 mg/wk, Mastabol 200 requires 1 ml per injection twice weekly — significantly less volume than the same dose in propionate format, which would require 2 ml per shot EOD. This matters for injection comfort across a 14-week cycle.
- No AI required for Mastabol 200 itself: AI management on the stack is determined by the testosterone base and any other aromatizing compounds — drostanolone enanthate contributes no estrogen regardless of dose or duration.
Drostanolone enanthate fills the space between the precision of a short-ester pre-contest compound and the full-cycle coverage that long lean phases require. Mastabol 200 from steroidwarehouse.com delivers British Dragon's 200 mg/ml drostanolone enanthate for users building a sustained, low-frequency injection protocol around a 12–16 week lean-phase or recomposition block — where the compound earns its place through consistency over the full cycle rather than a compressed final-weeks contribution.
References
| Source | Description | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| British Journal of Pharmacology / PubMed | Kicman AT 2008 — comprehensive review of anabolic-androgenic steroid pharmacology; covers androgen receptor binding, steroid metabolism, structure-activity relationships, ester pharmacokinetics, anabolic and androgenic mechanisms, detection methods, and adverse effects associated with AAS use | Kicman AT (2008) ↗ |
What is Mastabol 200?
Mastabol 200 is an injectable anabolic steroid (Drostanolone Enanthate) for muscle definition; see What is Mastabol 200. It's potent—consult professionals for safe use.
How long does Mastabol 200 stay in your system?
Detectable for ~2-3 months; see How Long Does Mastabol 200 Stay in Your System. Monitor with professional guidance.
How do I take Mastabol 200?
400-600 mg/week for men, 100-200 mg/week for women, injected weekly or bi-weekly; see How to Take Mastabol 200. Start low—consult professionals for dosing.
How to cycle Mastabol 200?
8-12 weeks, 400-600 mg/week, PCT after 10-14 days; see How to Cycle Mastabol 200. Stack with testosterone—consult professionals for protocols.
How long does it take to notice effects from Mastabol 200?
Because it contains the longer-acting enanthate ester, effects generally develop gradually over several weeks, with improvements in muscle hardness, conditioning, and physique appearance becoming more noticeable over time.
What are the main benefits of Mastabol 200?
Commonly reported benefits include enhanced muscle definition, increased muscle hardness, improved physique conditioning, support for lean muscle retention, and a drier appearance.
Is Mastabol 200 better for bulking or cutting?
Mastabol 200 is most commonly associated with cutting and recomposition phases due to its reputation for promoting a lean, hard, and defined physique.
What are the possible side effects of Mastabol 200?
Potential side effects may include acne, oily skin, hair loss in genetically predisposed individuals, and suppression of natural testosterone production.
Related Products
